ClinicalTrials.gg
Not yet recruitingNCT07895355Updated Oct 26, 2026

Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

A Phase 2 interventional study of RC148 plus Telisotuzumab adizutecan and RC148 plus Telisotuzumab adizutecan in Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy, sponsored by RemeGen Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

02

Conditions studied

  • Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
03

In context

Colorectal Neoplasms

6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.

This study's planned enrollment of 412 is above the median of 76 across 4,800 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 81 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the study and sign the form
  2. Be willing to and able to act on the trial and the follow-up procedures
  3. At least 18 years old
  4. (ECOG) performance status of 0 or 1
  5. ≥ 12 weeks
  6. Participants have or cytologically confirmed unresectable adenocarcinoma of the colon or rectum
  7. At least one lesion with based on v1.1 as determined by the local site investigator/radiology assessment
  8. All participants must have an evaluable c-Met expression result per central IHC testing, a RAS status report, and a MSI/MMR report prior to the first dose of study treatment
  9. Adequate bone marrow, hepatic, renal and coagulation functions
  10. Female participants must be or surgically sterilized, or must have a negative blood pregnancy test within 7 days prior to the first dose for women of , and agree to take at least one medically accepted measure during the treatment and within 12 months following the end of treatment, and must not donate eggs or breast-feeding. Male participants must agree to take at least one medically accepted contraceptive measure during the treatment period and within 12 months following the end of treatment, and must not donate sperm during this period

Exclusion criteria

Exclusion Criteria:

  1. Participants are dMMR/MSI-H or have known BRAF V600E mutation
  2. Known active and/or carcinomatous meningitis.
  3. The images during the screening indicating obvious necrosis or cavity in tumor that may increase the risk of hemorrhage as determined by investigators, tumor invasion of major blood vessels or vital organs, the risk of fistula, or tumor encasing major blood vessels, or imaging evidence indicating participating in the study may increase the risk of hemorrhage
  4. History of interstitial lung disease or pneumonitis that required treatment with systemic , or any evidence of active ILD/pneumonitis on screening chest CT scan
  5. History of idiopathic pulmonary fibrosis, organizing pneumonia, treatment-induced pneumonitis, idiopathic pneumonitis, or radiation pneumonitis
  6. History of , intercurrent lung-specific illnesses including
  7. Uncontrollable cardiovascular diseases
  8. Active inflammatory bowel disease (including but not limited to ulcerative colitis and Crohn's disease; Abdominal fistula, GI perforation, peptic ulcer, or intra-abdominal abscess within 6 months prior to the first dose; Imaging evidence of gastrointestinal obstruction or clinical symptoms and signs of gastrointestinal obstruction
  9. Ongoing serious, non-healing wound, ulcer, or bone fracture
  10. History of clinically significant arterial thrombotic or embolic events e.g., deep venous thrombosis, pulmonary embolism or cerebral vascular accident
  11. Active gastrointestinal bleeding, hemoptysis , peptic ulcer, or bleeding events requiring intervention within 28 days prior to the first dose; or had severe esophageal and gastric varices, epistaxis , or clinically significant coagulopathy
  12. Serious acute or chronic infections
  13. Third space effusion with clinical symptoms or requiring intervention.
  14. History of liver cirrhosis
  15. Uncontrolled diabetes
  16. Active or history of diseases that may relapse.
  17. History of other acquired or congenital immunodeficiency diseases or organ transplantation.
  18. Known history of prior except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy
  19. Toxicity not recovered from prior anticancer therapy, defined as not recovered to v6.0 Grade 1 or baseline level, or at the level specified in the inclusion/exclusion criteria,s.
  20. History of an allergic reaction or significant sensitivity to constituents of the study treatment and/or other products in the same class
  21. Have any other diseases, metabolic abnormalities, abnormal physical examinations or laboratory tests, indicating reasonable possibility, as determined by investigators, that the participants have diseases or conditions disqualified him/her for the drugs, the interpretation of the study results may be impacted, or the participants may be put at high risk
  22. Prior systemic regimen containing Irinotecan or c-Met targeting antibody or c-Met targeting ADC, or any Top1i ADC
  23. Received any prior tumor immunotherapy
  24. Participants treated with any investigational treatment within 28 days or 5 half-lives of the treatment prior to the first dose of study treatment or is currently enrolled in another clinical study or was previously enrolled in this study
  25. Received chest radiotherapy of > 30 Gy within 6 months prior to the first dose and/or received palliative local therapy within 2 weeks prior to the first dose
  26. Received nonspecific immunomodulatory therapy or received herbal supplements or traditional Chinese medicines that are intending to treat cancer within 1 weeks prior to the first dose of study drugs
  27. Participant has received any within 4 weeks prior to the first dose of study treatment, or expected need of live vaccination during study participation including at least 4 weeks after the last dose of study treatment
  28. Systemic treatment with corticosteroids or other drugs within 2 weeks prior to the first dose of study drugs
  29. Participants receiving anticoagulant drugs.
  30. Major surgical procedure within 28 days, or anticipation of the need for major surgical procedure during the study, and minor surgical procedure within 7 days prior to study enrollment
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
412 participants (estimated)

Study arms

  • Experimental
    Dose1 RC148 plus Dose1 Telisotuzumab adizutecan

    Drug: RC148 plus Telisotuzumab adizutecan

  • Experimental
    Dose2 RC148 plus Dose1 Telisotuzumab adizutecan

    Drug: RC148 plus Telisotuzumab adizutecan

  • Active comparator
    Dose1 Telisotuzumab adizutecan plus Bevacizumab

    Drug: Telisotuzumab adizutecan plus Bevacizumab

  • Experimental
    Dose3 RC148 plus Dose2 Telisotuzumab adizutecan plus 5-FU

    Drug: RC148 plus Telisotuzumab adizutecan

  • Experimental
    Dose4 RC148 plus Dose2 Telisotuzumab adizutecan plus 5-FU

    Drug: RC148 plus Telisotuzumab adizutecan

  • Active comparator
    Dose2 Telisotuzumab adizutecan plus Bevacizumab plus 5-FU

    Drug: Telisotuzumab adizutecan plus Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. ORR as assessed by the Investigator per RECIST v1.1

    Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months

  2. The incidence and severity of AEs, vital signs, physical examinations, ECGs, and laboratory test

    Time frame: Screening through 120 days after the last dose of RC148/telisotuzumab adizutecan/bevacizumab or 28 days after the last dose of 5-FU/LV, whichever is late

Secondary outcomes

  1. RC148 and Telisotuzumab adizutecan concentrations at each time-point post-dosing

    Time frame: 24 months

  2. Maximum concentration (Cmax) of RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  3. Time to Cmax (Tmax) of RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  4. Area under the concentration-time curve for a dosing interval (AUCtau) of RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  5. Area under the concentration-time curve extrapolated to infinity (AUCinf) of RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  6. Elimination half-life (t1/2) of RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  7. Incidence of ADA for RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  8. Onset timing of ADA for RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  9. Duration of ADA for RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  10. Titers of ADA for RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  11. Incidence of NAb for RC148 and Telisotuzumab adizutecan

    Time frame: 24 months

  12. PFS as assessed by the Investigator per RECIST v1.1

    Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months

  13. TTR as assessed by the Investigator per RECIST v1.1

    Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months

  14. DCR as assessed by the Investigator per RECIST v1.1

    Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months

  15. DoR as assessed by the Investigator per RECIST v1.1

    Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months

  16. OS as assessed by the Investigator per RECIST v1.1

    Time frame: From randomization date until lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 20 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 26, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jan 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07895355
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Jiang Guo
Contact
jiang.guo@remegen.com
010-65384976

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: RC148 · Telisotuzumab adizutecan

Start the discussion